Wave Life Sciences Ltd. shares promising updates on AATD & DMD treatments. Click here for my updated look at WVE stock ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

Participants in the FORWARD-53 trial had clinically significant improvements in time-to-rise, among other metrics.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Wave Life Sciences (WVE – Research Report) and ...

Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Wave Life Sciences in a research note issued to investors on Wednesday, March 26th. Leerink Partnrs ...

The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...

Wave Life Sciences Ltd.’s WVE share price has dipped by 10.08%, which has investors questioning if this is right time to buy.

Wave Life Sciences (WVE) shares ended the last trading session 6.1% higher at $10.02. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Wave Life Sciences (WVE) announced positive data from the Phase 2 FORWARD-53 trial of WVE-N531, which is an exon skipping oligonucleotide being ...

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Teacher Retirement System of Texas boosted its position in Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 57.6% during ...